{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:38:43Z","timestamp":1784115523308,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As per research, causing cancer cells to necroptosis might be used as a therapy to combat cancer drug susceptibility. Long non-coding RNA (lncRNA) modulates the necroptosis process in Skin Cutaneous Melanoma (SKCM), even though the precise mechanism by which it does so has yet been unknown. RNA sequencing and clinical evidence of SKCM patients were accessed from The Cancer Genome Atlas database, and normal skin tissue sequencing data was available from the Genotype-Tissue Expression database. Person correlation analysis, differential screening, and univariate Cox regression were successively utilized to identify necroptosis-related hub lncRNAs. Following this, we adopt the least absolute shrinkage and selection operator regression analysis to construct a risk model. The model was evaluated on various clinical characteristics using many integrated approaches to ensure it generated accurate predictions. Through risk score comparisons and consistent cluster analysis, SKCM patients were sorted either high-risk or low-risk subgroups as well as distinct clusters. Finally, the effect of immune microenvironment, m7G methylation, and viable anti-cancer drugs in risk groups and potential clusters was evaluated in further detail. Included USP30-AS1, LINC01711, LINC00520, NRIR, BASP1-AS1, and LINC02178, the 6 necroptosis-related hub lncRNAs were utilized to construct a novel prediction model with excellent accuracy and sensitivity, which was not influenced by confounding clinical factors. Immune-related, necroptosis, and apoptosis pathways were enhanced in the model structure, as shown by Gene Set Enrichment Analysis findings. TME score, immune factors, immune checkpoint-related genes, m7G methylation-related genes, and anti-cancer drug sensitivity differed significantly between the high-risk and low-risk groups. Cluster 2 was identified as a hot tumor with a better immune response and therapeutic effect. Our study may provide potential biomarkers for predicting prognosis in SKCM and provide personalized clinical therapy for patients based on hot and cold tumor classification.<\/jats:p>","DOI":"10.1038\/s41598-023-34238-0","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T10:02:59Z","timestamp":1683280979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive prediction of immune microenvironment and hot and cold tumor differentiation in cutaneous melanoma based on necroptosis-related lncRNA"],"prefix":"10.1038","volume":"13","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lushan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengdeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"issue":"10151","key":"34238_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf, D. et al. Melanoma. Lancet 392(10151), 971\u2013984 (2018).","journal-title":"Lancet"},{"key":"34238_CR2","doi-asserted-by":"crossref","unstructured":"Pasquali, S., Hadjinicolaou, A. V., Chiarion Sileni, V., Rossi, C. R. & Mocellin, S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst. Rev. 2020(11), (2018).","DOI":"10.1002\/14651858.CD011123.pub2"},{"issue":"3","key":"34238_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA: A Cancer J. Clin."},{"issue":"11","key":"34238_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis, L. E., Shalin, S. C. & Tackett, A. J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther. 20(11), 1366\u20131379 (2019).","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"34238_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.det.2019.05.001","volume":"37","author":"L Bomar","year":"2019","unstructured":"Bomar, L., Senithilnathan, A. & Ahn, C. Systemic therapies for advanced melanoma. Dermatol. Clin. 37(4), 409\u2013423 (2019).","journal-title":"Dermatol. Clin."},{"issue":"11","key":"34238_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","volume":"21","author":"S Bedoui","year":"2020","unstructured":"Bedoui, S., Herold, M. J. & Strasser, A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat. Rev. Mol. Cell Biol. 21(11), 678\u2013695 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"34238_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cell.2012.06.019","volume":"150","author":"J Li","year":"2012","unstructured":"Li, J. et al. The RIP1\/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150(2), 339\u2013350 (2012).","journal-title":"Cell"},{"issue":"3","key":"34238_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","volume":"39","author":"M Murphy James","year":"2013","unstructured":"Murphy James, M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39(3), 443\u2013453 (2013).","journal-title":"Immunity"},{"issue":"2","key":"34238_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbcan.2019.01.006","volume":"1871","author":"X Qin","year":"2019","unstructured":"Qin, X., Ma, D., Tan, Y.-X., Wang, H.-Y. & Cai, Z. The role of necroptosis in cancer: A double-edged sword?. Biochim. Biophys. Acta BBA Rev. Cancer 1871(2), 259\u2013266 (2019).","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"issue":"1","key":"34238_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.trecan.2021.09.003","volume":"8","author":"J Yan","year":"2022","unstructured":"Yan, J., Wan, P., Choksi, S. & Liu, Z.-G. Necroptosis and tumor progression. Trends Cancer 8(1), 21\u201327 (2022).","journal-title":"Trends Cancer"},{"issue":"2","key":"34238_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/icb.2016.120","volume":"95","author":"N Lalaoui","year":"2017","unstructured":"Lalaoui, N. & Brumatti, G. Relevance of necroptosis in cancer. Immunol. Cell Biol. 95(2), 137\u2013145 (2017).","journal-title":"Immunol. Cell Biol."},{"issue":"5","key":"34238_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1078-0432.CCR-16-0968","volume":"23","author":"L Seifert","year":"2017","unstructured":"Seifert, L. & Miller, G. Molecular pathways: The necrosome\u2014A target for cancer therapy. Clin. Cancer Res. 23(5), 1132\u20131136 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"34238_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong, Y. et al. The role of necroptosis in cancer biology and therapy. Mol. Cancer 18(1), 1\u201317 (2019).","journal-title":"Mol. Cancer"},{"issue":"8","key":"34238_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cells9081823","volume":"9","author":"J Sprooten","year":"2020","unstructured":"Sprooten, J. et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells 9(8), 1823 (2020).","journal-title":"Cells"},{"issue":"9","key":"34238_CR15","doi-asserted-by":"publisher","first-page":"e1884","DOI":"10.1038\/cddis.2015.240","volume":"6","author":"P Geserick","year":"2015","unstructured":"Geserick, P. et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 6(9), e1884\u2013e1884 (2015).","journal-title":"Cell Death Dis."},{"issue":"12","key":"34238_CR16","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41418-019-0315-8","volume":"26","author":"B Podder","year":"2019","unstructured":"Podder, B. et al. TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma. Cell Death Differ. 26(12), 2520\u20132534 (2019).","journal-title":"Cell Death Differ."},{"issue":"1","key":"34238_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/bib\/bbv031","volume":"17","author":"F Ferr\u00e8","year":"2016","unstructured":"Ferr\u00e8, F., Colantoni, A. & Helmer-Citterich, M. Revealing protein\u2013lncRNA interaction. Brief. Bioinform. 17(1), 106\u2013116 (2016).","journal-title":"Brief. Bioinform."},{"issue":"3","key":"34238_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","volume":"172","author":"F Kopp","year":"2018","unstructured":"Kopp, F. & Mendell, J. T. Functional classification and experimental dissection of long noncoding RNAs. Cell 172(3), 393\u2013407 (2018).","journal-title":"Cell"},{"issue":"5","key":"34238_CR19","first-page":"205","volume":"23","author":"J Li","year":"2016","unstructured":"Li, J., Meng, H., Bai, Y. & Wang, K. Regulation of lncRNA and Its role in cancer metastasis. Oncol. Res. Featur. Preclin. Clin. Cancer Ther. 23(5), 205\u2013217 (2016).","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"issue":"15","key":"34238_CR20","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan, A., Soleimani, M. & Mandal, S. S. Long noncoding RNA and cancer: A new paradigm. Can. Res. 77(15), 3965\u20133981 (2017).","journal-title":"Can. Res."},{"issue":"11","key":"34238_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nm.3981","volume":"21","author":"M Huarte","year":"2015","unstructured":"Huarte, M. The emerging role of lncRNAs in cancer. Nat. Med. 21(11), 1253\u20131261 (2015).","journal-title":"Nat. Med."},{"issue":"4","key":"34238_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt, A. M. & Chang, H. Y. Long noncoding RNAs in cancer pathways. Cancer Cell 29(4), 452\u2013463 (2016).","journal-title":"Cancer Cell"},{"issue":"9","key":"34238_CR23","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1002\/jcp.26568","volume":"233","author":"WD Yu","year":"2018","unstructured":"Yu, W. D., Wang, H., He, Q. F., Xu, Y. & Wang, X. C. Long noncoding RNAs in cancer-immunity cycle. J. Cell. Physiol. 233(9), 6518\u20136523 (2018).","journal-title":"J. Cell. Physiol."},{"key":"34238_CR24","doi-asserted-by":"publisher","first-page":"107591","DOI":"10.1016\/j.pharmthera.2020.107591","volume":"213","author":"Q Hu","year":"2020","unstructured":"Hu, Q., Egranov, S. D., Lin, C. & Yang, L. Long noncoding RNA loss in immune suppression in cancer. Pharmacol. Ther. 213, 107591 (2020).","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"34238_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01727-3","volume":"39","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Liu, Q. & Liao, Q. Long noncoding RNA: A dazzling dancer in tumor immune microenvironment. J. Exp. Clin. Cancer Res. 39(1), 1\u201325 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"34238_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/ijms18040715","volume":"18","author":"G Richtig","year":"2017","unstructured":"Richtig, G. et al. Function and clinical implications of long non-coding RNAs in melanoma. Int. J. Mol. Sci. 18(4), 715 (2017).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"34238_CR27","doi-asserted-by":"crossref","first-page":"e12698","DOI":"10.1111\/cpr.12698","volume":"53","author":"L Tang","year":"2019","unstructured":"Tang, L., Liang, Y., Xie, H., Yang, X. & Zheng, G. Long non-coding RNAs in cutaneous biology and proliferative skin diseases: Advances and perspectives. Cell Prolif. 53(1), e12698 (2019).","journal-title":"Cell Prolif."},{"issue":"8","key":"34238_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14(8), 463\u2013482 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"34238_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9235638","volume":"2020","author":"M Ralli","year":"2020","unstructured":"Ralli, M. et al. Immunotherapy in the treatment of metastatic melanoma: Current knowledge and future directions. J. Immunol. Res. 2020, 1\u201312 (2020).","journal-title":"J. Immunol. Res."},{"issue":"17","key":"34238_CR30","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"Weiss, S. A., Wolchok, J. D. & Sznol, M. Immunotherapy of melanoma: Facts and hopes. Clin. Cancer Res. 25(17), 5191\u20135201 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"34238_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo, W., Wang, H. & Li, C. Signal pathways of melanoma and targeted therapy. Signal Transduct. Target. Ther. 6(1), 424 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"34238_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16(1), 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"issue":"36","key":"34238_CR33","doi-asserted-by":"publisher","first-page":"eaaw2004","DOI":"10.1126\/sciimmunol.aaw2004","volume":"4","author":"AG Snyder","year":"2019","unstructured":"Snyder, A. G. et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci. Immunol. 4(36), eaaw2004 (2019).","journal-title":"Sci. Immunol."},{"issue":"1","key":"34238_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang, R. et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J. Hematol. Oncol. 13(1), 1\u201318 (2020).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"34238_CR35","doi-asserted-by":"publisher","first-page":"e000489","DOI":"10.1136\/jitc-2019-000489","volume":"8","author":"M Di Martile","year":"2020","unstructured":"Di Martile, M. et al. Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages. J. Immunother. Cancer 8(1), e000489 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"34238_CR36","doi-asserted-by":"publisher","first-page":"728319","DOI":"10.3389\/fonc.2021.728319","volume":"11","author":"L Nicol\u00e8","year":"2021","unstructured":"Nicol\u00e8, L. et al. RIPK3 and AXL expression study in primary cutaneous melanoma unmasks AXL as predictor of sentinel node metastasis: A pilot study. Front. Oncol. 11, 728319 (2021).","journal-title":"Front. Oncol."},{"issue":"1","key":"34238_CR37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41467-019-08541-2","volume":"10","author":"HM Haikala","year":"2019","unstructured":"Haikala, H. M. et al. Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nat. Commun. 10(1), 620 (2019).","journal-title":"Nat. Commun."},{"issue":"1","key":"34238_CR38","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1038\/ncomms13898","volume":"7","author":"TA Aguilera","year":"2016","unstructured":"Aguilera, T. A. et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat. Commun. 7(1), 13898 (2016).","journal-title":"Nat. Commun."},{"issue":"11","key":"34238_CR39","doi-asserted-by":"publisher","first-page":"8909","DOI":"10.1002\/jcb.27144","volume":"119","author":"YY Li","year":"2018","unstructured":"Li, Y. Y. et al. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma. J. Cell. Biochem. 119(11), 8909\u20138921 (2018).","journal-title":"J. Cell. Biochem."},{"key":"34238_CR40","doi-asserted-by":"crossref","unstructured":"Lin, Z., Fan, W., Sui, X., Wang, J. & Zhao, J. Necroptosis-related LncRNA signatures for prognostic prediction in uterine corpora endometrial cancer. Reproduct. Sci. (2022).","DOI":"10.1007\/s43032-022-01023-9"},{"issue":"1","key":"34238_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-0929-6","volume":"37","author":"L Xu","year":"2018","unstructured":"Xu, L. et al. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J. Exp. Clin. Cancer Res. 37(1), 1\u201315 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"34238_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2022.5122","volume":"49","author":"M Schott","year":"2022","unstructured":"Schott, M. et al. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma. Int. J. Mol. Med. 49(5), 1\u201313 (2022).","journal-title":"Int. J. Mol. Med."},{"key":"34238_CR43","first-page":"1","volume":"2021","author":"Y Ding","year":"2021","unstructured":"Ding, Y. et al. A novel autophagy-related lncRNA gene signature to improve the prognosis of patients with melanoma. Biomed. Res. Int. 2021, 1\u201312 (2021).","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"34238_CR44","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1111\/cas.15140","volume":"112","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. LncRNA BASP1-AS1 interacts with YBX1 to regulate Notch transcription and drives the malignancy of melanoma. Cancer Sci. 112(11), 4526\u20134542 (2021).","journal-title":"Cancer Sci."},{"issue":"11","key":"34238_CR45","doi-asserted-by":"publisher","first-page":"19471","DOI":"10.1002\/jcp.28740","volume":"234","author":"M Ashrafizadeh","year":"2019","unstructured":"Ashrafizadeh, M. et al. Autophagy, anoikis, ferroptosis, necroptosis, and endoplasmic reticulum stress: potential applications in melanoma therapy. J. Cell. Physiol. 234(11), 19471\u201319479 (2019).","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"34238_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01599-7","volume":"39","author":"W Luan","year":"2020","unstructured":"Luan, W. et al. Long non-coding RNA LINC00520 promotes the proliferation and metastasis of malignant melanoma by inducing the miR-125b-5p\/EIF5A2 axis. J. Exp. Clin. Cancer Res. 39(1), 1\u201316 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10304","key":"34238_CR47","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398(10304), 1002\u20131014 (2021).","journal-title":"Lancet"},{"issue":"11","key":"34238_CR48","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.3390\/ijms21114071","volume":"21","author":"M Olbryt","year":"2020","unstructured":"Olbryt, M., Rajczykowski, M. & Wid\u0142ak, W. Biological factors behind melanoma response to immune checkpoint inhibitors. Int. J. Mol. Sci. 21(11), 4071 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"34238_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18(3), 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"34238_CR50","doi-asserted-by":"publisher","first-page":"641507","DOI":"10.3389\/fimmu.2021.641507","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang, M., Song, J., Yuan, W., Zhang, W. & Sun, Z. Roles of RNA methylation on tumor immunity and clinical implications. Front. Immunol. 12, 641507 (2021).","journal-title":"Front. Immunol."},{"issue":"1","key":"34238_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-022-01285-5","volume":"15","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. The potential role of N7-methylguanosine (m7G) in cancer. J. Hematol. Oncol. 15(1), 63 (2022).","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"34238_CR52","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1016\/j.molcel.2021.06.031","volume":"81","author":"EA Orellana","year":"2021","unstructured":"Orellana, E. A. et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Mol. Cell 81(16), 3323\u20133338 (2021).","journal-title":"Mol. Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34238-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T04:56:27Z","timestamp":1702356987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34238"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34238-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7299"}}